You are here

IdentifySensors Biologics

Summary

Make an investment in IdentifySensors Biologics.

New Digital Nanosensors Soon Will Replace 50-Year-Old Chemical PCR Tests

Every “new” COVID test that hits the market relies on the same longstanding chemical reactions discovered more than 50 years ago. IdentifySensors Biologics and Purdue University have developed new digital nanosensors intended to rapidly detect COVID-19 and a host of other infections as accurately as a PCR test.

This is the technological breakthrough intended to move medical testing past antiquated chemistry and into the digital era. Soon, it is intended that consumers and businesses will have an over-the-counter electronic device in their medicine cabinet.

Similar to a home pregnancy test, personal diagnostic technology is intended to accurately and rapidly detect COVID-19, COVID variants, influenza, measles, mumps, STDs and host of other infections. All current chemical-reaction tests soon are inteneded to be replaced by fast and affordable digital nanosensors that connect easily to a smartphone. 

Before the pandemic, Purdue University was developing the nanosensors to detect pathogens far more effectively than current chemical tests. When COVID-19 hit, Purdue accelerated its research and focused on coronavirus testing. Today, Purdue is in discussions with the FDA for approval of a highly accurate, over-the-counter testing system.     

The Check4 brand is intended to be a disruptive technology that will include multiple sub-brands for a range of infections, such as Check4-COVID, Check4-Flu and Check4-MRSA. The technology is intended to make current chemical-based tests, such as PCR and antigen tests, obsolete.

INVESTMENT OVERVIEW

Purdue University and IdentifySensors Biologics have partnered to create Check4™: a highly accurate, over-the-counter platform device intended to quickly detect COVID-19 RNA and a host of other infections using all-new digital nanosensors, saliva and a smartphone to pinpoint infections that rapid chemical tests miss more than 50 percent of the time.

The reusable reader is intended to cost $130. Each COVID test cartridge is intended to cost less than $25. Both are intended to be released to the public with EAU approval very soon This patented and patent-pending technology is intended to also detect variant strains of COVID-19, influenza, HIV/AIDS, STDs, lyme disease, measles and other pathogens—offering investors extraordinary value well beyond the pandemic. 

This new technology platform is intended to significantly disrupt the diagnostics industry. It is intended that consumers soon will have a testing laboratory in their home medicine cabinet, with the ability to diagnose many infections at home, without a prescription.

 COMPLETELY DIFFERENT TECHNOLOGY

The Check4 platform, including Check4-COVID™ is not a PCR test, an antibody test or an antigen test. These three technologies make up nearly all current COVID diagnostics. Check4 is all-new technology based on electronic nanosensors that measure electrical currents passing through pathogens. This technology, which is in the final stages of development at Purdue University, requires no amplification, no reagents and no nasal swabs. It is intended to be an over-the-counter saliva self-test as effective as a PCR test, but without a prescription, high costs or delayed results.    

Ready to invest?

Call our investment team at 737-757-8067

Family office and institutional investors click here.

→ A GLOBAL PROBLEM ←

New CDC research found that people who don't show COVID symptoms may be responsible for 59 percent of transmissions. This includes 35 percent who are presymptomatic and 24 percent who never develop symptoms at all. The new Check4-COVID nanosensor technology is intended to catch these infections, as well as variant strains at home or on the go, fulfilling a significant gap in managing the pandemic and other infectious diseases.

 

→ ANSWERING A GLOBAL NEED←

Antigen test results are wrong most of the time. PCR tests require a doctor, a lab and long waits. A highly accurate, affordable portable test that can be taken routinely at home or on the go, is the breakthrough that will enable people to return to work, attend events and travel. There is currently no portable, over-the-counter test that is both accurate and accessible to offer full social confidence. Check4-COVID™ uses all-new electronic nanosensor technology intended to disrupt over-the-counter home diagnostics for many pathogens the same way home pregnancy tests changed family planning. 

Businesses

Family

Public

Ready to invest?

Call our investment team at 737-757-8067. Help get this test to market soon.

Family office and institutional investors click here.

FUTURE-READY TECHNOLOGY

Check4-COVID™ is intended to meet an immediate public need, but our technology has the capability to go beyond COVID-19 testing to provide rapid results among a wide range of pathogens. Our focus for the near future include:

THE GOLD STANDARD IN ACCURACY

Most home tests produce a high percentage of false positives and false negatives. With the help of infectious disease specialists at Purdue University, we’ve designed Check4-COVID™ to meet the gold-standard in hospital-grade molecular testing, but taken entirely at home without a prescription and long wait times.

Why Do Current COVID Tests Give False Results?

The accuracy of current tests depends on:

A good sample or nasal swab that is well preserved and transported to a lab without contamination. Current home tests rely on untrained users.

Amplification of the virus. Current chemical tests can’t detect COVID-19 without amplification. In many cases, samples have insufficient virus material, requiring the test to multiply the virus millions of times.

Preparing the sample. Once a sample safely reaches a laboratory, it is chemically treated. If the wrong reagents are used, or if they have deteriorated, this offers yet another opportunity for error.

What Makes Check4-COVID™ Different from Current Tests?

Check4-COVID™ accurately detects COVID-19 through newly developed nanosensors, without the need for a lab, amplification or chemical reactions. This means:

No need to transport a clean sample to a lab and risk contamination.

No amplification of the virus is needed.

No need to prepare the sample in a lab for machine testing.

Ready to invest?

Help get this test to market soon. Call our investment team at 737-757-8067

Family office and institutional investors click here.

MEET OUR LEADERSHIP

Our team includes world-leading scientists, executives and business advisors, who ensure our ability to deliver this test to market soon. We have the expertise and credentials to bring Check4-COVID™ to consumers, hospitals and point-of-care facilities worldwide.

Executives

Gregory Hummer

Co-Founder & CEO

Bruce Raben

President

Tommy Sors

COO

Ann Hawkins

CFO

Jeff Spagnola

CMO

Technology

Lia Stanciu

CSO

Amit Barui

Research Associate

Rupesh Mishra

Research Scientist

Rodney Corder

CPO

Advisors

Richard Kuhn

Virologist

Dick Buell

Marketing

Stephan Barrett

Finance

OUR COLLECTIVE EXPERTISE INCLUDES:

The director of Purdue University's Institute of Inflammation Immunology and Infectious Diseases, who worked with the recent Nobel Prize-winning team.

The assistant director of Purdue's Institute of Inflammation, Immunology and Infectious Diseases, whose renowned work focused on molecular biology.

One of the world's leading researchers in materials engineering at Purdue University.

A leading biomedical researcher at Purdue University.

A former Cleveland Clinic Surgeon and NASA Consultant.

A biomedical engineering professor at North Carolina State University, who has published more than 200 peer-reviewed articles in biomedical materials.

A former CMO of Cisco Systems.

A founding partner of Hudson Capital Advisors.

A former electrical engineering manager for Rockwell Automation.

A former CFO of Whirlpool and Procter & Gamble.

A former CEO of Catalina Marketing Corp., who serves on the boards of the American Society of Mechanical Engineers, SC Johnson, and Prestige Brands.

THE OPPORTUNITY

Your investment will help us to
manufacture, market, and distribute
Check4-COVID™ worldwide.

Ready to invest?

Call our investment team at 737-757-8067. Help get this test to market soon.

Family office and institutional investors click here.

Investor Updates

February 9th Update

In the News

Check4-COVID™ FAQs

Product Questions

1. What does IdentifySensors Biologics do?
Check4-COVID™ is intended to be a fast, accurate and affordable saliva self-test for COVID-19. Results are displayed within minutes on a smartphone app, with accuracy that far exceeds current rapid home tests. 

2. How is Check4 COVID different from all other COVID tests?
New CDC research shows that current rapid home tests give false results more than 50 percent of the time. Check4-COVID is intended to be an entirely at-home instant test with accuracy above 90 percent. Reducing false negatives by this margin will be critical to curbing the pandemic and slowing the spread.   

3. Do healthcare professionals need to administer the test?
No. Check4-COVID™ is intended to be a simple self-test, similar to a home DNA test. Check4-COVID™ allows consumers to test their saliva on a device that connects to a smartphone. Results appear on the app within minutes in the privacy of a user’s home.

4. How does the test work?
Consumers buy a small, simple device online or from a retail store and download the free smartphone app. A saliva sample is placed in the device, and the results appear within minutes on the app. It is intended that inexpensive replaceable cartridges will allow endless, affordable testing on each device.

5. How accurate is Check4-COVID™?
Following FDA approval, Check4-COVID™ intends to meet the gold-standard in hospital-grade molecular COVID testing with minimal false positives. This is significantly better than current home rapid tests. 

6. Why does the test notify health authorities?
By law, all COVID test results must be reported to health authorities to help manage the pandemic. Check4-COVID™ is an electronic-based, self-test that fulfills legal reporting requirements automatically through smartphones.

7. Why does the test use a smartphone app?
Chemical-based tests often rely on visual indicators. Check4-COVID™ uses an electronic circuit, which enables a signal to be sent to smartphones. The app then reports results to health authorities, which is required by law.

8. What if I don’t have a smartphone?
The smartphone app allows multiple users on a single device. This enables family members who do not have smartphones to use the device and app belonging to someone with a smartphone.

9. Do I have to buy multiple devices to test other family members?
No. A family can share the same device. The smartphone app is intended to allow multiple users so family members can share the same app and device, while interchanging different test cartridges.

10. Is the Smartphone app HIPAA compliant? What happens to my personal information?
By law, all test results must be reported to state and federal health authorities. All information collected by the IdentifySensors app is confidential and shared only with government agencies that require it. Some test results are de-identified, meaning that names are removed from the test results. All data is treated by the same high standards as secure hospital records. The app is securely encrypted and fully HIPAA compliant.

11. Can I turn off the reporting function of the app?
No. By law, all test results for contagious diseases must be reported to state, and federal health authorities. All information collected by the Check4-COVID™ app is encrypted, confidential, and follows high hospital standards for HIPAA-compliant privacy.

12. How much will the test cost?
It is intended that the reusable reader will cost $130. Each test cartridge will cost less than $25. The accuracy of the test and the low cost are intended to promote more frequent testing.

13. How can I be sure the test is accurate?
World-renowned scientists at Purdue University, who specialize in infectious diseases, have been developing and verifying the test’s accuracy for commercialization. The test is intended to be available to consumers following FDA approval, which is anticipated this year.

14. What is the problem with current rapid tests?
New CDC research shows that more than 50 percent of current rapid test results are incorrect. Most PCR tests currently in use are expensive and take far too long for the results. These chemical-based tests often require samples to be transported to a laboratory for results.

15. When will the test be available to consumers?
Industry-leading scientists at Purdue University who specialize in infectious diseases have been developing and verifying the test for commercialization. The test is intended to be available to consumers following FDA approval this year.

16. Where will the test be sold?
Check4-COVID™ is intended to be sold online and through retail stores, such as pharmacies and grocery stores. High-volume commercial versions of the test are intended to be available to healthcare facilities and businesses through wholesale channels.

17. Can the test be used to minimize quarantine times?
Yes. Check4-COVID™ is intended to be fast, inexpensive and accurate, which enables frequent self-testing at home and without wait. Individuals infected with COVID-19, who quarantine at home, can self-test as often as they like to minimize quarantine times and return to their lives as soon as possible.

18. Is the test technology patented?
Yes, IdentifySensors holds several patents on various facets of the technology. Other patents are pending.

19. When will the product be available on the market?
Product development is in its final stages now. It is intended that the test will be available in 2021, following FDA approval.

20. How long will the FDA approval process take?
Check4-COVID™ soon will be submitted for FDA approval. We cannot be sure how long that process will last, but the process typically lasts a few weeks.

21. What plans does the company have for the product have after the pandemic?
The unique technology enables the test to be easily modified for other pathogens, including other coronaviruses, influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox, and methicillin-resistant staphylococcus Aureus (MRSA), as well as foodborne pathogens.

Pandemic Questions

22. How will this test help curb the pandemic?
The majority of COVID transmissions are spread by asymptomatic and early infections. PCR tests can take days for the results, and rapid home tests are incorrect more than 50 percent of the time. Check4-COVID is intended to provide immediate results with the accuracy of a PCR lab test. It is the best of both tests. Experts agree that vaccines and the combination of instant and accurate testing holds the key to curbing the pandemic.  

23. How can businesses benefit from this test?
Customers and employees could be allowed into facilities more readily with more frequent testing. Offices, manufacturing facilities, and restaurants, for example, could require self-tests of their employees. Sports facilities, airlines, and concert halls, for example, could require fans to display their self-test results on their smartphones before entering.

24. How will the test benefit hospitals, health care facilities, and nursing homes?
The self-tests are intended to be fast, accurate and affordable. Frontline workers and nursing-home employees, for example, could test themselves, and their patients daily, and isolate positive cases. Slowing the spread of the virus can help hospitals manage the best use of their facilities.

Investment Questions

25. Why did you use Regulation A+ and not venture capital or other types of funding?
Regulation A+ opens investment opportunities to anyone, regardless of their wealth or income. IdentifySensors biologics wanted to offer this opportunity to everyone interested in this exciting project. IdentifySensors Biologics is particularly well-suited for Regulation A+ because of the welcoming atmosphere the company provides.

26. What happens now that I’ve made an investment?
IdentifySensors Biologics will communicate news regularly. Our first messages will be about processing your investment payment and issuing your shares. Beyond that, we will notify you regularly about company milestones. As a Regulation A+ company, we are required to make annual and semi-annual filings with the SEC, all of which will be available on the SEC’s EDGAR filing system. The filings include:

  • Annual filings on Form 1-K, which are due each year and include audited financial statements for the previous fiscal year.
  • Semi-annual filings on Form 1-SA, which will include unaudited financial statements for the previous six months.
  • Form 1-U will announce important company events, such as leadership changes, a change in auditors, or certain types of capital-raising.

 

27. Can I invest if I am outside of the United States?
Yes. Investors around the world are welcome to invest. However, certain country restrictions might apply. Investors should consult their legal advisers about their ability to invest. Investors in Canada are prevented from investing in Regulation A+ by Canadian securities regulations.

28. How do I sell my shares?
These shares are not intended to list on a major exchange after the Regulation A+ offering. Because the shares are currently not listed on a stock exchange, there is no active market. However, these securities will not be restricted and can be freely traded to the extent any market develops for them from the date that an investor receives their shares. This is an advantage of Regulation A+ compared to other public offerings of private companies because securities regulations allow investors to sell their shares immediately. We intend to list our shares on a new Regulation A+ aftermarket listing services, which we intend to select after we complete this offering. We expect initially that there will be limited liquidity in this market. The company currently has no plans to seek listing or quotation of the securities on the NASDAQ, NYSE, or the OTC markets. In the future, the company may choose to list the company on a major public stock exchange to bring liquidity to the shares

29. Can I still invest if I am not an accredited investor?
Yes, investors of any wealth level over 18 years of age may participate in the Regulation A+ offering.

30. Do my shares have voting rights?
Yes, one vote per share.

31. Can I add shares to my initial investment?
Yes, but each new investment must be at least $300.

Ready to invest?

Call our investment team at 737-757-8067. Help get this test to market soon.

Family office and institutional investors click here.

Comments

Post comment

IdentifySensors Biologics on December 23
Our investment team was asked: "How is Manhattan Street Capital being compensated?" The Answer: Manhattan Street Capital is a paid fixed consulting and listing fees. For each investment, the company is paid $25 in cash and warrants on our stock.

  •  

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/25045

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.